Lifeboat Foundation

Dell Technologies expands its computing (HPC) portfolio, offering powerful solutions to help organizations quickly innovate with confidence.

With a range of new offers, Dell delivers technologies and services to help power demanding applications while making HPC capabilities more accessible to businesses.

Dell PowerEdge servers champion advanced modeling and datasets.

Disney is adding another layer to its AI and extended reality strategies. As first reported by Reuters, the company recently formed a dedicated emerging technologies unit. Dubbed the Office of Technology Enablement, the group will coordinate the company’s exploration, adoption and use of artificial intelligence, AR and VR tech.

It has tapped Jamie Voris, previously the CTO of its Studios Technology division, to oversee the effort. Before joining Disney in 2010, Voris was the chief technology officer at the National Football League. More recently, he led the development of the company’s Apple Vision Pro app. Voris will report to Alan Bergman, the co-chairman of Disney Entertainment. Reuters reports the company eventually plans to grow the group to about 100 employees.

“The pace and scope of advances in AI and XR are profound and will continue to impact consumer experiences, creative endeavors, and our business for years to come — making it critical that Disney explore the exciting opportunities and navigate the potential risks,” Bergman wrote in an email Disney shared with Engadget. “The creation of this new group underscores our dedication to doing that and to being a positive force in shaping responsible use and best practices.”

Richard Scolyer was fully engaged in the business of living when he suddenly received a death sentence. A person more alive would be hard to find. As an endurance athlete competing across the globe, he was in peak physical condition. As one of the world’s leading pathologists on melanoma whose pioneering research has saved thousands of lives, he was in demand. At 56, Prof Richard Scolyer was flying along. His life, he says, was “rich”. And then, on the morning of 20 May 2023, he found himself losing consciousness and convulsing on the floor in a hotel room in Poland, panicking and scared.

After this grand mal seizure, he went for an MRI scan at University hospital in Krakow. It found a mass in his temporal lobe. Scolyer knew immediately it had delivered very bad news.

Related: When I found out about the brain tumour that would kill me, I faced my worst fears – but I chose to take it on.

Google is doubling down on AI internally to make its business more efficient.

Prof. Leslie Leiserowitz first became intrigued by malaria when he was a young boy in South Africa. His father, who scouted the continent in search of wood for the family business, brought back not only tales of elephants and gorillas but also skin rashes and ringing in his ears, side effects of the quinine he took to prevent malaria.

In this interview I speak with Chris Fronda, CEO of Logictry.

In this interview Bruce Burke speaks with Chris Fronda, CEO of Logictry. Scaling the world’s wisdom to help everyone make better decisions faster. Chris is presenting at Fin+AI 2024 Conference, October 2–4, 2024 at Le Meridien in Dania Beach, Florida. Meet Chris and other leaders at Fin+AI.

Continue reading “Fin+AI 2024 Interview | Chris Fronda, Co-Founder and Chief Logic Officer, Logictry on AI & Education” »

Palantir is helping companies incorporate AI into their businesses — and one analyst says it’s succeeded ‘more than any company (not named Nvidia)’

Businesses are embracing AI agents that ‘don’t eat’ and can work 24/7.

Mike Kelly is President & Chief Executive Officer of NervGen Pharma Corp. (https://nervgen.com/), a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease.

NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in an initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Continue reading “Mike Kelly — President & CEO, NervGen Pharma — Innovative Treatments To Enable Nervous System Repair” »